Improved joint health in haemophilia A patients treated prophylactically with Elocta /Eloctate - SOBI + Bioverativ.
Swedish Orphan Biovitrum AB (publ) (Sobi)and Bioverativ Inc. announce the publication of interim results from a longitudinal study of joint health in patients treated prophylactically with Elocta (efmoroctocog alfa)/Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the treatment of haemophilia A. Interim data show participants enrolled in the ASPIRE extension study demonstrated continuous improvement in joint health over a nearly three-year period with prophylactic dosing of Elocta/Eloctate, regardless of prior treatment regimen, severity of joint damage or target joints. Joint health improvements were most notable in haemophilia A patients with poor joint health. These results were published online 30 October, 2017 in Haemophilia.
This interim post hoc analysis evaluated joint health in adult and adolescent participants in the A-LONG and ASPIRE studies using the modified Haemophilia Joint Health Score (mHJHS), a first-line assessment tool that grades joints by specific domains, including swelling, muscle atrophy, alignment, range of motion, joint pain, strength and global gait. The study examined mHJHS measurements (a decrease in score reflecting improvement) taken at A-LONG baseline and ASPIRE baseline and annually thereafter for nearly three years of treatment.
In the study, adults and adolescents (n=47) treated prophylactically with Elocta/Eloctate experienced a mean improvement in joint health score of -4.1 at ASPIRE year 2, compared with A-LONG baseline. Regardless of pre-study treatment regimen, subjects showed continuous improvement in mHJHS from A-LONG baseline through ASPIRE year 2 (pre-study prophylaxis: -2.4; pre-study episodic treatment: -7.2) and benefits were seen in subjects with target joints (-5.6) as well as those with severe joint destruction (-8.8). The mHJHS components with the greatest improvement at ASPIRE year 2 were swelling (-1.4), range of motion (-1.1) and strength (-0.8)[i].
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins